Boston, MA – Odyssey Therapeutics has announced the appointment of Jolie Siegel as Executive Vice President, General Counsel. Odyssey Therapeutics is a biotechnology company dedicated to transforming the standard of care for patients suffering from autoimmune and inflammatory diseases. The company focuses on targeting upstream signaling nodes and mechanisms within the innate immune system to prevent pathological inflammation before it occurs, differentiating its approach from existing treatments that often address inflammation after it has begun. Odyssey has developed a pipeline of small molecule and protein therapeutics designed to precisely target disease pathology, prioritizing areas with significant unmet medical needs and large patient populations. Their scientific strategy aims to unlock the immune system’s untapped potential by preventing initial immune responses, which they believe can lead to long-lasting, deep remission with less immunosuppressive risk compared to current therapies.

For more information on Odyssey Therapeutics please visit: https://odysseytx.com/

Website: https://odysseytx.com/
Company LinkedIn Page: https://www.linkedin.com/company/odyssey-tx/

Odyssey Therapeutics
51 Sleeper St #800
Boston, MA 2210
Phone: 617-865-9628

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved